Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint
Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.
You may also be interested in...
South African researchers make own version of mRNA COVID-19 vaccine that uses “recipes” available in the public domain but one that is eventually expected to be “second generation” and can be more applicable to use in low- and middle-income countries. The initiative, under the wider WHO-backed mRNA vaccine technology hub, doesn’t see Moderna or BioNTech intellectual property as being a barrier.
Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.
Coronavirus Notebook: South Africa To Build mRNA Vaccine Tech Transfer Hub, EMA OKs More Comirnaty Production Capacity
MSF is pressuring Moderna and Pfizer/BioNTech to share their vaccine know-how with manufacturers in developing countries, and companies have just a few days to answer the European Commission's questions about COVID-19 therapies they have in development.